Overview

Cambridge Brain Mets Trial 1

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Collaborators:
Boehringer Ingelheim
Cancer Research UK
The Brain Tumour Charity
University of Cambridge
Treatments:
Afatinib